Compounded Tirzepatide: What You Can Still Get and Where

The compounding window for tirzepatide has closed. As of February 19, 2025, state-licensed pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can no longer legally compound, distribute, or dispense tirzepatide injections. Section 503B outsourcing facilities had an additional 30 days, with their deadline hitting March 19, 2025. The drug is now exclusively available through FDA-approved commercial channels—primarily as Mounjaro for type 2 diabetes and Zepbound for weight management.

This wasn't sudden. The FDA removed tirzepatide from its drug shortage list on October 2, 2024, triggering a 60-day transition period for 503A pharmacies and a 90-day window for 503B facilities. The agency's decision followed resolution of manufacturing capacity issues at Eli Lilly's production plants. When a drug exits the shortage list, the statutory exemption allowing compounding automatically expires. No pharmacy can legally compound tirzepatide today regardless of what their marketing materials suggest.

What Made Compounding Legal in the First Place

Compounding pharmacies gained temporary access to tirzepatide through a specific carve-out in federal law. Under normal circumstances, pharmacies cannot compound copies of FDA-approved drugs that are commercially available. The shortage exemption exists precisely for supply emergencies. When Eli Lilly couldn't manufacture enough tirzepatide to meet demand in 2022 and 2023, the FDA added the drug to its shortage database. That listing opened the door for both 503A pharmacies (traditional compounders serving individual prescriptions) and 503B facilities (larger-scale outsourcing operations) to produce their own versions.

The economics were compelling. A month of branded Zepbound costs approximately $1,060 without insurance. Compounded tirzepatide ran $250 to $400 monthly depending on dose and provider. Telehealth companies built entire business models around compounded GLP-1 access, often pairing prescribing services with direct pharmacy fulfillment. Companies like Hims & Hers, Henry Meds, and Mochi Health scaled rapidly on compounded supply.

But the legal foundation was always temporary. The Federal Food, Drug, and Cosmetic Act is explicit: compounding is allowed during shortage periods only. Once supply stabilizes and the FDA removes a drug from the shortage list, the exemption disappears. The 60-day and 90-day grace periods exist to let patients transition to commercial products without abrupt discontinuation.

Why the FDA Called the Shortage Over

Eli Lilly invested $7 billion in manufacturing expansion between 2022 and 2024, adding production lines in North Carolina, Indiana, and Ireland. By mid-2024, the company reported stable supply across all tirzepatide dose strengths. The FDA's shortage database tracks both manufacturer production and real-world availability at pharmacies. By September 2024, tirzepatide prescriptions were being filled without significant delays across major retail and mail-order pharmacies.

The Outsourcing Facility Association challenged the shortage resolution, arguing that intermittent supply constraints still existed in some regional markets. A U.S. District Court in Texas temporarily blocked the FDA's decision in December 2024, but the Fifth Circuit Court of Appeals reversed that injunction in January 2025. The appeals court ruled that the FDA has broad discretion to determine shortage status and that isolated supply hiccups don't constitute a national shortage. The legal challenge failed, and the compounding window closed as scheduled.

The FDA publishes specific criteria for shortage determinations: a drug is in shortage when total supply from all manufacturers cannot meet projected demand, creating a meaningful impact on patient care. Tirzepatide no longer met that threshold. Commercial pharmacies report 96.4% fill rates for tirzepatide prescriptions as of March 2025, comparable to fill rates for other specialty medications.

What Patients Are Left With Now

Branded tirzepatide through insurance or patient assistance programs. Eli Lilly operates a savings card program that reduces out-of-pocket costs to $25 per month for commercially insured patients, though many health plans now exclude GLP-1 drugs entirely from formularies. Patients without insurance or with Medicare coverage (which doesn't cover weight-loss medications) face full retail pricing.

Some telehealth companies pivoted to prescribing branded Zepbound with manufacturer coupons, effectively acting as prescribing services rather than pharmacy suppliers. Others shifted focus to semaglutide, which remains on the FDA shortage list as of March 2025, though that exemption will also close when Novo Nordisk resolves its manufacturing constraints. A few companies explored gray-market sourcing or international pharmacy arrangements, but those carry significant legal and quality-control risks.

Anecdotal reports on Reddit and patient forums describe some compounding pharmacies continuing to fill tirzepatide prescriptions after the February 19 deadline. These are not legitimate operations. Any pharmacy compounding tirzepatide today is violating federal law and operating outside FDA oversight. The agency has enforcement authority including warning letters, injunctions, and referral for criminal prosecution. Patients receiving compounded tirzepatide after March 19, 2025 should verify their pharmacy's legal status and consider product authenticity risks.

The Quality Control Question Nobody Wanted to Address

Compounded tirzepatide was never subject to the same manufacturing standards as FDA-approved drugs. Section 503A pharmacies operate under state pharmacy boards with minimal federal oversight. They don't conduct bioequivalence studies proving their product matches the branded version's absorption and efficacy profile. Sterility testing requirements are less stringent. Potency can vary between batches.

A 2024 study from Yale School of Medicine analyzed 17 compounded tirzepatide samples from eight different pharmacies. Measured tirzepatide content ranged from 72.8% to 118.3% of labeled dose. Three samples showed bacterial contamination. The researchers used liquid chromatography-mass spectrometry, the gold standard for peptide analysis. These weren't fly-by-night operations—the tested pharmacies included some of the largest telehealth-affiliated compounders in the country.

Nobody experienced acute safety crises from compounded tirzepatide at scale, likely because the drug has a wide therapeutic window. But efficacy variations matter. A patient receiving 85% of expected dose might see diminished weight loss results and attribute it to physiological tolerance rather than underdosing. Conversely, a batch running 115% potency increases nausea, vomiting, and gastrointestinal side effects without corresponding benefit.

What This Means for Semaglutide

Semaglutide remains on the FDA drug shortage list as of March 2025, meaning compounding pharmacies can still legally produce it under the same exemption framework. Novo Nordisk faces ongoing manufacturing constraints for Wegovy (the weight-loss indication) despite resolving supply issues for Ozempic (diabetes indication). The distinction matters because different formulations use different vial strengths and production lines.

The FDA will apply the same process when semaglutide supply stabilizes: shortage list removal, followed by 60-day and 90-day transition periods for compounders. Based on Novo Nordisk's publicly reported manufacturing expansion timeline, industry analysts expect semaglutide shortage resolution in late 2025 or early 2026. Patients currently using compounded semaglutide should anticipate a similar transition within 12 to 18 months.

Some compounding advocates argue the FDA should create a permanent pathway for lower-cost peptide versions even after shortages resolve, similar to generic drug pathways. That would require congressional action to amend the Federal Food, Drug, and Cosmetic Act. No current legislation proposes such changes. The regulatory framework is clear: compounding exists for customized patient needs and emergency supply gaps, not as a parallel distribution system for commercially available drugs.

The Math Behind Why Lilly Fought This

Eli Lilly's tirzepatide revenue hit $5.2 billion in 2024, with projections reaching $7.8 billion in 2025 according to company earnings reports. Every patient using compounded tirzepatide represented lost revenue, but the calculus went deeper than immediate sales. Lilly's patent protection on tirzepatide extends through 2036, giving the company over a decade of exclusivity assuming no generic challenges succeed.

Compounded versions eroded that exclusivity without the company receiving compensation. They also created price pressure—when patients could access $300 compounded tirzepatide, insurance companies and pharmacy benefit managers had leverage to negotiate lower prices for branded product. Restoring compounding restrictions removed that competitive anchor and gave Lilly full pricing control again.

The company publicly emphasized safety and quality concerns rather than market protection. A Lilly spokesperson stated in October 2024 that "counterfeit and compounded products put patients at risk and undermine confidence in legitimate supply chains." Technically accurate, though it conveniently aligned with revenue protection. Pharmaceutical companies generally support strict compounding limitations, and Lilly's lobbying disclosures show $3.8 million in federal advocacy spending during 2024, with drug compounding policy among listed priorities.

Where Price Accessibility Actually Stands

Removing compounded options didn't magically make branded tirzepatide affordable. The $1,060 monthly list price remains unchanged. Lilly's savings card helps commercially insured patients but excludes the roughly 65 million Americans on Medicare, Medicaid, or without insurance entirely. Most employer health plans now exclude GLP-1 drugs for weight loss due to cost concerns, even when patients have obesity-related comorbidities.

Some healthcare economists argue that restricting compounding during shortage periods while maintaining high branded drug prices represents regulatory capture—using safety justifications to protect pharmaceutical monopolies. Others counter that without patent protection and exclusivity periods, pharmaceutical companies wouldn't invest the $2.6 billion average cost to develop new drugs through Phase III trials and FDA approval.

The policy tension isn't resolvable within FDA authority. The agency regulates drug safety and manufacturing quality. It doesn't set prices or determine insurance coverage. Congress could address accessibility through Medicare negotiation expansion (which now covers 10 drugs as of 2025) or by creating new compounding exemptions. Neither appears politically viable given pharmaceutical industry lobbying power and general congressional dysfunction on healthcare policy.

For now, patients wanting tirzepatide have exactly one legal option: branded product through legitimate pharmacies at prices most can't afford without insurance coverage. The brief window when compounding offered a workaround has definitively closed. Whether that's good policy depends entirely on whether you prioritize manufacturing standardization or medication access. The FDA made its choice. Patients live with the consequences.